{"title":"The interaction between instrumental activities of daily living and dual sensory function on cognition among the elderly in China: A cross-sectional survey","authors":"Heting Liang, Zhixia Jiang, Xiaoling Yang, Shuang Li, Xiaoling Zhao, Yongya Dai, Siqin Liu, Yumeng Zhang, Xiaoli Yuan","doi":"10.1002/ibra.12124","DOIUrl":"10.1002/ibra.12124","url":null,"abstract":"<p>To explore the interaction of instrumental activities of daily living (IADLs) and dual sensory function on cognition in the elderly. A cross-sectional survey was conducted in six general hospitals in China, from October 2022 to December 2022. Data collection included general information, IADLs scale, self-reported sensory function questionnaire, and mini-mental state examination (MMSE). Binary logistic regression was used to examine the association between factors and cognition. The interactive effect was evaluated by synergy index (S), relative excess risk due to interaction (RERI), and attributable proportion due to interaction (AP). The odds ratio (OR) of IADLs decline in cognition is 4.412 (95% confidence interval [CI]: 3.633–5.358, <i>p</i> < 0.001); the OR of dual sensory difficulty on cognition is 2.502 (95% CI: 1.272–4.921, <i>p</i> = 0.008). The OR of interaction between IADLs decline and dual sensory difficulty on cognition is 13.737 (95% CI: 9.726–19.400, <i>p</i> < 0.001). RERI (95% CI) = 7.823 (3.230–12.417), AP (95% CI) = 0.570 (0.392–0.747), S (95% CI) = 2.593 (1.616–4.160). IADLs decline and dual sensory difficulty are associated with cognitive decline. IADLs decline and dual sensory difficulty have interaction with cognitive decline; the interaction is greater than the sum effect of those two on cognitive decline independently. Sensory and IADLs assessment can be used as early screening items for cognition among the elderly. In addition, protecting sensory function and maintaining IADLs in the elderly can help protect their cognition.</p>","PeriodicalId":94030,"journal":{"name":"Ibrain","volume":"9 3","pages":"281-289"},"PeriodicalIF":0.0,"publicationDate":"2023-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ibra.12124","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41163400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IbrainPub Date : 2023-08-06DOI: 10.1002/ibra.12122
Xing-Yu Yang, Xiao Zhang, Jun-Feng Cao, Mei Wu, Sheng-Yan Chen, Li Chen
{"title":"Routes and methods of neural stem cells injection in cerebral ischemia","authors":"Xing-Yu Yang, Xiao Zhang, Jun-Feng Cao, Mei Wu, Sheng-Yan Chen, Li Chen","doi":"10.1002/ibra.12122","DOIUrl":"10.1002/ibra.12122","url":null,"abstract":"<p>Cerebral ischemia is a serious cerebrovascular disease with the characteristics of high morbidity, disability, and mortality. Currently, stem cell therapy has been extensively applied to a wide range of diseases, including neurological disorders, autoimmune deficits, and other diseases. Transplantation therapy with neural stem cells (NSCs) is a very promising treatment method, which not only has anti-inflammatory, antiapoptotic, promoting angiogenesis, and neurogenesis effects, but also can improve some side effects related to thrombolytic therapy. NSCs treatment could exert protective effects in alleviating cerebral ischemia-induced brain damage and neurological dysfunctions. However, the different injection routes and doses of NSCs determine diverse therapeutic efficacy. This review mainly summarizes the various injection methods and injection effects of NSCs in cerebral ischemia, as well as proposes the existing problems and prospects of NSCs transplantation.</p>","PeriodicalId":94030,"journal":{"name":"Ibrain","volume":"9 3","pages":"326-339"},"PeriodicalIF":0.0,"publicationDate":"2023-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ibra.12122","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41170259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IbrainPub Date : 2023-07-15DOI: 10.1002/ibra.12120
Ya Chen, Xia Zhang, Hai‐Qing Zhang, Zhong Luo, Xueyan Zhou, Tao Liang, Fei Yang, Jun Zhang, Zucai Xu
{"title":"Study on the efficacy of compound porcine cerebroside and ganglioside injection in patients with ischemic stroke: A randomized, single‐center, open‐label, prospective study","authors":"Ya Chen, Xia Zhang, Hai‐Qing Zhang, Zhong Luo, Xueyan Zhou, Tao Liang, Fei Yang, Jun Zhang, Zucai Xu","doi":"10.1002/ibra.12120","DOIUrl":"https://doi.org/10.1002/ibra.12120","url":null,"abstract":"","PeriodicalId":94030,"journal":{"name":"Ibrain","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80607080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IbrainPub Date : 2023-07-13DOI: 10.1002/ibra.12118
Xue Zheng, Jing Li, Zhao‐Qiong Zhu
{"title":"Progress of research on antiferroptosis and antipyroptosis effects of gastrodin","authors":"Xue Zheng, Jing Li, Zhao‐Qiong Zhu","doi":"10.1002/ibra.12118","DOIUrl":"https://doi.org/10.1002/ibra.12118","url":null,"abstract":"","PeriodicalId":94030,"journal":{"name":"Ibrain","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75080195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Development of an innovative minimally invasive primate spinal cord injury model: A case report","authors":"Yong-Min Niu, Jin-Xiang Liu, Hao-Yue Qin, Yi-Fan Liu, Ni-Jiao Huang, Ji-Li Jiang, Yan-Qiu Chen, Si-Jing Chen, Tao Bai, Chang-Wei Yang, Yu Cao, Sheng Liu, Hao Yuan","doi":"10.1002/ibra.12117","DOIUrl":"10.1002/ibra.12117","url":null,"abstract":"<p>Spinal cord injury (SCI) animal models have been widely created and utilized for repair therapy research, but more suitable experimental animals and accurate modeling methodologies are required to achieve the desired results. In this experiment, we constructed an innovative dorsal 1/4 spinal cord transection macaque model that had fewer severe problems, facilitating postoperative care and recovery. In essence, given that monkeys and humans share similar genetics and physiology, the efficacy of this strategy in a nonhuman primate SCI model basically serves as a good basis for its prospective therapeutic use in human SCI.</p>","PeriodicalId":94030,"journal":{"name":"Ibrain","volume":"9 3","pages":"349-356"},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ibra.12117","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41165732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IbrainPub Date : 2023-07-06DOI: 10.1002/ibra.12119
Yunan Wang, Hua Yang, Jun Su, Xiaobin Jian, Peijie Li, Jianguo Zhou, Wei Hu
{"title":"Transformation of a low-grade glioma into a glioblastoma along with the development of lung and mediastinal lymph node metastases after repeated craniotomy: A case report","authors":"Yunan Wang, Hua Yang, Jun Su, Xiaobin Jian, Peijie Li, Jianguo Zhou, Wei Hu","doi":"10.1002/ibra.12119","DOIUrl":"10.1002/ibra.12119","url":null,"abstract":"<p>Extracranial metastasis of glioma is extremely rare. Herein, we report a case of glioblastoma that originated and showed stepwise malignant transformation from a low-grade glioma (LGG) along with the presence of lung and mediastinal lymph node metastases after repeated craniotomy. A 30-year-old man presented with hemoptysis. Thoracic computed tomography revealed a space-occupying lesion in the right upper lung with mediastinal nodal and metastases in both lungs; lung cancer was suspected. The patient's medical history showed that he had undergone craniotomy three times in 7 years for a primary LGG disease relapse, and stepwise malignant-transformed high-grade glioma (HGG). However, brain magnetic resonance imaging did not reveal any relapse of intracranial tumors. The diagnosis of extracranial metastatic glioblastoma was confirmed using the morphology and staining results for specific immunohistochemistry markers using the specimen obtained via endobronchial ultrasound transbronchial needle aspiration. Subsequently, the patient received a combination of systemic and local treatments; however, he died of massive hemoptysis after 6 months. The survival time of this glioma patient improved after transformation and metastasis. Detailed descriptions will help us understand the biological behavior of glioma, but more studies are needed to confirm the complex mechanism of extracranial metastasis.</p>","PeriodicalId":94030,"journal":{"name":"Ibrain","volume":"10 3","pages":"385-389"},"PeriodicalIF":0.0,"publicationDate":"2023-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ibra.12119","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83250451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IbrainPub Date : 2023-06-25DOI: 10.1002/ibra.12116
Guo-Fang Zhang, Tao Liang, Yi-Kun Lv, Zhong Luo, Jun Zhang
{"title":"Bilateral hearing loss caused by anti-NMDA receptor encephalitis with teratoma: A case report","authors":"Guo-Fang Zhang, Tao Liang, Yi-Kun Lv, Zhong Luo, Jun Zhang","doi":"10.1002/ibra.12116","DOIUrl":"10.1002/ibra.12116","url":null,"abstract":"<p>Autoimmune encephalitis (AE) is an autoimmune disease in the central nervous system. Clinical manifestations include cognitive dysfunction, psychiatric-behavioral abnormalities, epilepsy, motor disorders, speech disorders, and memory impairment. Some patients do not have the characteristic clinical manifestations of the disease when they see a doctor, so they are easily diagnosed incorrectly. Autoimmune antibodies originate from genetic and acquired factors. Clinical data have found a correlation between ovarian teratoma and autoimmune encephalitis. This case reports a 34-year-old woman who was diagnosed with teratoma-associated anti-N-methyl-D- aspartate receptor-mediated autoimmune encephalitis called anti-N-methyl-D-aspartate receptor encephalitis with bilateral hearing loss in 2021. Through this case report, clinicians will pay attention to autoimmune encephalitis and raise awareness of the specific clinical manifestations of autoimmune encephalitis, and focus on early identification. It means that clinicians should be familiar with the representative clinical manifestations of the disease.</p>","PeriodicalId":94030,"journal":{"name":"Ibrain","volume":"10 3","pages":"378-384"},"PeriodicalIF":0.0,"publicationDate":"2023-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ibra.12116","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75912984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IbrainPub Date : 2023-06-06DOI: 10.1002/ibra.12098
Bin-Can Tang, Ya-Ting Wang, Jie Ren
{"title":"Basic information about memantine and its treatment of Alzheimer's disease and other clinical applications","authors":"Bin-Can Tang, Ya-Ting Wang, Jie Ren","doi":"10.1002/ibra.12098","DOIUrl":"10.1002/ibra.12098","url":null,"abstract":"<p>Memantine is a noncompetitive moderate-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist. It has been used to treat Alzheimer's disease (AD) since 1989. In 2018, it became the second most commonly used drug for the treatment of dementia in the world. AD is nonreversible, and memantine can only relieve the symptoms of AD but not cure it. Over the past half-century, memantine's research and clinical application have been extensively developed. In this review, the basic composition of memantine, the mechanism and limitations of memantine in the treatment of AD, memantine combination therapy, comparison of memantine with other drugs for AD, and clinical studies of memantine in other diseases are reviewed to provide a valuable reference for further research and application of memantine for the treatment of AD.</p>","PeriodicalId":94030,"journal":{"name":"Ibrain","volume":"9 3","pages":"340-348"},"PeriodicalIF":0.0,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ibra.12098","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41176393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A case report of the treatment and care of decubitus ulcers in macaques with spinal cord injury","authors":"Yong-Min Niu, Hao-Yue Qin, Jin-Xiang Liu, Xin-Yi Li, An-Su Wang, Ling-Xia Sun, Ni-Jiao Huang, Chang-Wei Yang, Yu Cao, Tao Bai, Yang Lan, Sheng Liu, Hao Yuan","doi":"10.1002/ibra.12105","DOIUrl":"10.1002/ibra.12105","url":null,"abstract":"<p>Decubitus ulcers are a common spinal cord injury (SCI) complication that puts patients' lives in danger and has emerged as a more prevalent issue in modern clinical rehabilitation and care. Decubitus ulcers in humans can currently be treated in a number of different ways, but there are fewer studies on how to treat and care for decubitus ulcers in macaques. To treat a 20-year-old adult male macaque monkey with SCI and decubitus ulcers after a quarter transection of the thoracic spinal cord, a number of scientific care procedures and pharmaceutical treatments, such as dietary changes and topical or intravenous administration of medication, were carried out and continuously monitored in real-time. In comparison to the untreated group, we observed a significant improvement in decubitus wound healing in the macaques. In this article, we provide a good protocol for decubitus ulcer care after SCI and suggest that future experimental animal modeling needs to focus on issues such as care for postoperative complications.</p>","PeriodicalId":94030,"journal":{"name":"Ibrain","volume":"9 2","pages":"236-242"},"PeriodicalIF":0.0,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ibra.12105","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41126107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IbrainPub Date : 2023-05-22DOI: 10.1002/ibra.12107
Ji-Yan Wang, Xin-Tong Dai, Qing-Le Gao, Hong-Kai Chang, Shuai Zhang, Chang-Liang Shan, Tao He
{"title":"Tyrosine metabolic reprogramming coordinated with the tricarboxylic acid cycle to drive glioma immune evasion by regulating PD-L1 expression","authors":"Ji-Yan Wang, Xin-Tong Dai, Qing-Le Gao, Hong-Kai Chang, Shuai Zhang, Chang-Liang Shan, Tao He","doi":"10.1002/ibra.12107","DOIUrl":"10.1002/ibra.12107","url":null,"abstract":"<p>Due to the existence of the blood–brain barrier in glioma, traditional drug therapy has a poor therapeutic outcome. Emerging immunotherapy has been shown to have satisfactory therapeutic effects in solid tumors, and it is clinically instructive to explore the possibility of immunotherapy in glioma. We performed a retrospective analysis of RNA-seq data and clinical information in 1027 glioma patients, utilizing machine learning to explore the relationship between tyrosine metabolizing enzymes and clinical characteristics. In addition, we also assessed the role of tyrosine metabolizing enzymes in the immune microenvironment including immune infiltration and immune evasion. Highly expressed tyrosine metabolizing enzymes 4-hydroxyphenylpyruvate dioxygenase, homogentisate 1,2-dioxygenase, and fumarylacetoacetate hydrolase not only promote the malignant phenotype of glioma but are also closely related to poor prognosis. The expression of tyrosine metabolizing enzymes could distinguish the malignancy degree of glioma. More importantly, tyrosine metabolizing enzymes regulate the adaptive immune process in glioma. Mechanistically, multiple metabolic enzymes remodel fumarate metabolism, promote α-ketoglutarate production, induce programmed death-ligand 1 expression, and help glioma evade immune surveillance. Our data suggest that the metabolic subclass driven by tyrosine metabolism provides promising targets for the immunotherapy of glioma.</p>","PeriodicalId":94030,"journal":{"name":"Ibrain","volume":"9 2","pages":"133-147"},"PeriodicalIF":0.0,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ibra.12107","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41163401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}